November 8, 2019 12:18 pm
The European Commission has approved the use of Epidyolex, a pharmaceutical grade cannabidiol (CBD), for the treatment of two types of severe childhood epilepsy.
The medication, developed by GW Pharmaceuticals, has been under trial for the treatment of Dravet Syndrome and Lennox Gastaut Spectrum, both of which are conditions that can result in multiple daily seizures.
Ley Sander, Medical Director at the UK’s Epilepsy Society and Professor of Neurology at University College London, said: “There is evidence to show that pharmaceutical grade CBD, under the trade name Epidyolex, is effective in reducing seizures in some children with Dravet Syndrome and Lennox Gastaut Spectrum.
“These are both severe childhood epilepsies which can be very debilitating. This new drug will bring hope for some families and European approval feels like a positive step.”
Professor Sander continued: “It is important that the medical profession, regulatory and advisory bodies remain level-headed in ensuring that the medications prescribed to people in the UK are rigorously tested and economically viable.
“If a drug holds promise in treating a condition, it is important that it is available for all those who require it and that it does not become another victim of a postcode lottery.”